Financial Performance - Abbott Laboratories shares slumped Thursday after narrowing its full-year outlook [1] - Abbott posted better-than-expected quarterly results [1] Market Dynamics - Demand for COVID-19 tests declines [1]

Company Restructuring - Sarepta Therapeutics 宣布重大重组计划 [1] Stock Market Impact - Sarepta Therapeutics 股票在盘后交易中飙升近 40% [1]

Company Overview - Madrigal (MDGL) shares increased by 10.9% to close at $344.97, with notable trading volume compared to typical sessions, and an overall gain of 11.3% over the past four weeks [1][2] Patent and Market Exclusivity - Madrigal received a Notice of Allowance for a new U.S. patent for Rezdiffra, its FDA-approved drug for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), which is valid through 2044 and will enhance market exclusivity by blocking generics [2] Financial Performance Expectations - The company is expected to report a quarterly loss of $3.64 per share, reflecting a year-over-year increase of 48.7%, while revenues are projected to be $160.13 million, up 993.8% from the previous year [3] Earnings Estimate Trends - The consensus EPS estimate for Madrigal has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Comparison - Madrigal operates within the Zacks Medical - Drugs industry, where another company, Corcept Therapeutics (CORT), closed 2% higher at $72.85, with a return of -0.6% over the past month [4]

Core Viewpoint - The market experienced a strong upward trend, with the ChiNext Index leading the gains, reflecting a significant interest in AI hardware and innovative pharmaceutical sectors [1] Market Performance - The total trading volume in the Shanghai and Shenzhen markets reached 1.54 trillion, an increase of 97.3 billion compared to the previous trading day [1] - Over 3,500 stocks in the market saw an increase, indicating a broad-based rally [1] Sector Highlights - AI hardware stocks surged, with companies like New Yisheng and Dongshan Precision reaching new historical highs [1] - Military stocks were active, with AVIC Shenfei also achieving a historical high [1] - Innovative pharmaceutical stocks maintained strong performance, with companies like Chengdu Xian Dao hitting the daily limit [1] - The top-performing sectors included CPO, military, PCB, and innovative pharmaceuticals, while real estate, gas, banking, and electricity sectors lagged behind [1] Index Performance - By the end of the trading session, the Shanghai Composite Index rose by 0.37%, the Shenzhen Component Index increased by 1.43%, and the ChiNext Index climbed by 1.76% [1]

Core Insights - Albertsons Companies experienced a 25% increase in digital sales for the quarter ending June 14, significantly outpacing the 2.8% increase in identical sales [2] - The company's loyalty program membership grew by 14%, reaching a total of 47 million members [5] Digital Sales and Engagement - The growth in digital sales has increased eCommerce's share of total grocery revenue to 9% during the quarter, attributed to improvements in customer service and the mobile app [3] - Ongoing investments in strategic priorities have driven increased engagement across digital platforms, including enhancements like artificial intelligence and interactive features for customer communication [4] Loyalty Program - The loyalty program has been simplified and enhanced, leading to increased member engagement and spending [5] - Members are utilizing more features of the program, resulting in more frequent interactions with the company [5] Future Outlook - The company views eCommerce as a significant growth opportunity for customer acquisition and retention beyond 2025, despite current penetration being below industry peers [4] - The eCommerce business is nearing breakeven in terms of profitability, indicating potential for future growth [4]

Company Overview - Zevra Therapeutics (ZVRA) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting a favorable outlook for investors [3] Price Performance - ZVRA shares have increased by 28.64% over the past week, significantly outperforming the Zacks Medical - Drugs industry, which rose by 1.75% during the same period [5] - Over the past month, ZVRA's price change is 45.18%, compared to the industry's 1.25% [5] - In the last quarter, ZVRA shares have risen by 74.97%, and over the past year, they have gained 95.57%, while the S&P 500 has only moved 16.04% and 12.11%, respectively [6] Trading Volume - ZVRA's average 20-day trading volume is 1,122,698 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Estimates - In the past two months, three earnings estimates for ZVRA have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $0.31 to $1.35 [9] - For the next fiscal year, two estimates have also moved upwards, with no downward revisions during the same period [9] Conclusion - Given the strong momentum indicators and positive earnings outlook, ZVRA is positioned as a solid momentum pick for investors [11]

Core Insights - Johnson & Johnson (JNJ) reported second-quarter 2025 earnings of $2.77 per share, exceeding the Zacks Consensus Estimate of $2.66, but reflecting a 1.8% decline year over year [1] - Total sales reached $23.74 billion, surpassing the Zacks Consensus Estimate of $22.80 billion, with a year-over-year increase of 5.8% [2] - The company raised its 2025 sales forecast to a range of $93.2 billion to $93.4 billion, indicating a growth of 5.1% to 5.6% compared to previous expectations [18][19] Financial Performance - Adjusted earnings, excluding intangible amortization and special items, were reported at $2.77 per share, while reported earnings, including these items, were $2.29 per share, up 18.7% year over year [1] - Domestic sales increased by 7.8% to $13.54 billion, while international sales rose by 3.2% to $10.2 billion [3] Segment Performance - The Innovative Medicines segment saw sales rise by 4.9% year over year to $15.2 billion, driven by strong performances from key products like Darzalex and Erleada [5][6] - The MedTech segment reported sales of $8.54 billion, up 7.3% from the previous year, benefiting from operational growth and currency impacts [16] Product Highlights - Darzalex sales increased by 23.0% to $3.54 billion, outperforming estimates [7] - Stelara sales declined by 42.7% to $1.65 billion due to biosimilar competition [11][12] - New drugs such as Carvykti and Tecvayli contributed significantly to sales growth, with Carvykti recording $439 million in sales [10] Future Outlook - JNJ anticipates operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half of 2025 [25] - The company considers 2025 a "catalyst year" for growth, despite challenges such as the Stelara patent cliff and ongoing legal issues [26]

Group 1 - Akebia Therapeutics (AKBA) is outperforming the Medical sector with a year-to-date return of approximately 104.2%, while the sector has returned an average of -5.7% [4] - The Zacks Consensus Estimate for AKBA's full-year earnings has increased by 65.4% in the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] - Akebia Therapeutics holds a Zacks Rank of 1 (Strong Buy), suggesting it has characteristics that may lead to outperformance in the market over the next one to three months [3] Group 2 - Akebia Therapeutics is part of the Medical - Drugs industry, which consists of 155 companies and currently ranks 96 in the Zacks Industry Rank, with an average gain of 4.1% this year [6] - Another Medical stock, ResMed (RMD), has returned 10.2% year-to-date and has a Zacks Rank of 2 (Buy), with a consensus EPS estimate increase of 1.4% over the past three months [5] - The Medical - Products industry, which includes ResMed, has 84 stocks and is ranked 166, with an average return of 4.8% since the beginning of the year [6]

Industry Overview - The uncertainty surrounding tariffs and trade measures has impacted economic growth, with President Trump threatening to impose tariffs as high as 200% on pharmaceutical imports to encourage domestic production [1] - Despite these threats, the biotech sector has remained stable, with many global pharmaceutical companies already investing in domestic manufacturing [1] Current Trends - The Zacks Medical-Drugs industry is showing promising trends due to positive pipeline and regulatory developments [2] - Key areas of innovation include rare diseases, next-generation oncology treatments, obesity, immunology, and neuroscience, attracting significant investor interest [3] M&A Activity - M&A activity in the sector remains healthy, indicating growth potential for companies like Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics, and Larimar Therapeutics [3] Industry Characteristics - The Zacks Medical-Drugs industry consists of small to medium-sized drug companies that produce medicines for human and veterinary use, often relying on collaboration payments for revenue [4] Factors Influencing Future Growth - The success of key pipeline candidates in clinical studies can significantly impact stock prices, with successful innovations acting as catalysts [5] - Strong collaboration with larger drugmakers is a positive indicator for small pharma companies, especially when equity investments are involved [6] - Investment in technology and personalized medicine is crucial for smaller companies to thrive in a changing healthcare landscape [7] Performance Metrics - The Zacks Medical-Drugs industry currently holds a Zacks Industry Rank of 96, placing it in the top 39% of 245 Zacks industries, indicating strong prospects [9] - Year-to-date, the industry has risen 5.6%, outperforming the Zacks Medical sector, which has decreased by 2.9%, while slightly underperforming the S&P 500, which has risen by 6.9% [11] Valuation - The industry is currently trading at a trailing 12-month price-to-sales ratio of 2.32, compared to the S&P 500's 5.66 and the Zacks Medical sector's 2.37 [12] Company Highlights - **Catalyst Pharmaceuticals**: Lead drug Firdapse shows strong demand; stock has risen 0.4% this year; earnings estimate for 2025 increased from $2.23 to $2.25 [16][17] - **Theravance Biopharma**: Strong sales from Yupelri; stock has risen 22.6% this year; earnings estimate for 2025 declined from 3 cents to 1 cent [20][21] - **Larimar Therapeutics**: Developing nomlabofusp for Friedreich's ataxia; stock has declined 18.3% this year; loss estimate for 2025 narrowed from $1.90 to $1.89 [24][25] - **Zevra Therapeutics**: Early adoption of Miplyffa exceeds expectations; stock has risen 53.4% this year; earnings estimate for 2025 increased from 31 cents to 76 cents [28][29] - **Aldeyra Therapeutics**: Focused on RASP modulators; stock has declined 0.4% this year; loss estimate for 2025 narrowed from $1.03 to 90 cents [31][32]

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced a new global distribution agreement with SMARTOX®, a Texas-based leader in drug and alcohol screening services, to bring its SmarTest Patch drug detection product to international markets outside of the United States ("U.S") and Canada. This partnership builds on the long-standing relat ...